Brooks Laboratories' Q1 FY 2025-26 Quarterly Results

Result Summary

• Brooks Laboratories Ltd reported a 40.0% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Jun (Q1 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 42.9%.
• Its expenses for the quarter were up by 27.7% QoQ and 26.7% YoY.
• The net profit decreased 199.7% QoQ and decreased 497.5% YoY.
• The earnings per share (EPS) of Brooks Laboratories Ltd stood at 3.3 during Q1 FY 2025-26.

Financial Statments for Q1 FY 2025-26

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Brooks Laboratories Ltd is a pharmaceutical company engaged in the manufacture and sale of active pharmaceutical ingredients (APIs) and formulations. The company operates within the healthcare and pharmaceutical industry, focusing on delivering high-quality therapeutic products. Brooks Laboratories Ltd has been involved in developing a diverse range of products catering to various therapeutic segments. As of the latest data, there are no specific recent developments mentioned within the provided context.

Revenue

In Q1FY26, Brooks Laboratories Ltd reported a total income of ₹25.73 crores, marking a significant increase from ₹18.38 crores in Q4FY25 and ₹18.00 crores in Q1FY25. This reflects a quarter-over-quarter (QoQ) growth of 40.0% and a year-over-year (YoY) growth of 42.9%. The substantial rise in total income indicates a robust performance in revenue generation for this quarter compared to the previous periods. The YoY growth suggests a stronger revenue position compared to the same quarter last year.

Profitability

The company's profitability metrics indicate a notable improvement in Q1FY26. Brooks Laboratories Ltd reported a profit before tax of ₹2.65 crores, compared to a mere ₹0.30 crores in Q4FY25 and a loss of ₹0.21 crores in Q1FY25. This resulted in a substantial QoQ growth of 783.3% and a dramatic YoY improvement of -1361.9%, moving from a negative to a positive profit before tax. The profit after tax was recorded at ₹9.58 crores, a remarkable turnaround from a loss of ₹9.61 crores in Q4FY25 and a loss of ₹2.41 crores in Q1FY25. This shows a QoQ change of -199.7% and a YoY change of -497.5%. The earnings per share (EPS) also shifted positively, moving from negative values in the previous quarters to ₹3.30 in Q1FY26.

Operating Metrics

The total expenses for Brooks Laboratories Ltd in Q1FY26 were ₹23.07 crores, showing an increase from ₹18.07 crores in Q4FY25 and ₹18.21 crores in Q1FY25. This represents a QoQ increase of 27.7% and a YoY increase of 26.7%. Despite the rise in expenses, the company has managed to improve its profitability significantly. The data provided does not include specific figures for taxes, which remained at zero across all periods. Additionally, the financial data does not provide other operating or financial ratios, such as the P/E ratio or current ratio, limiting further analysis in this section.